Navigation Links
First Patient Enrolled in Cogentus Pharmaceuticals' Pivotal Phase 3 Trial of Novel Combination Medicine
Date:1/15/2008

n 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America.

Among patients who participate in the study, approximately half will receive clopidogrel and aspirin; the other half will receive CGT-2168 (clopidogrel plus omeprazole) and aspirin. Patients will be assessed regularly for any gastrointestinal side effects such as bleeding and ulcers as well as receive ongoing monitoring of their cardiovascular status.

Physicians and patients interested in obtaining more information about COGENT-1 should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...HAM,Mass.,Nov.25/PRNewswire/--AccordingtoMillenniu...hnologymarketintelligence,thenearly$3billionUSmark...owthoverthenextfiveyearsdespitetherecenteconomicsl...tfindsthatthismarketwillremainhighlydynamicoverthe...ddevicesinpreviouslyunderservedsegmentsofthetrauma...
(Date:11/25/2009)...T,TheNetherlandsandJOHANNESBURG,November25/PRNewsw...xisDiscoveryannouncedtoday,thattheyhavesignedacoll...rvices. , Pyxis,sworldclasscomputationalchemi...emba,sservicedivisiontoprovidemedicinaland,synthet...,internationalclientnetwork.iThembaPharmaceutical...
(Date:11/24/2009)...NE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,...eatmentsforaorticdisorders,announcedtodaythatithas...hepatentinfringementlawsuitbroughtagainstitinOctob...sDistrictCourtinIndianapolis,Indiana. ,, Endolo...itedStatesPatentandTrademarkOffice(USPTO)conductsp...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 1AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 2AMA Honors Medical Society Executives 60901 1AMA Honors Medical Society Executives 60901 2AMA Has Chance to Rescind Support of HR 3962 3B AMA Shout Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership 60899 1
...--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeuti...om a Phase 3 clinical trial,of Fampridine-SR in pe...Academy of Neurology meeting. Andrew Goodman, M.D.... University of,Rochester, presented top-line resul...d clinician and subject global impressions.,Dr. Go...
...OD CITY, Calif., May 02, 2007 /PRNewswire-FirstCal...that a presentation was,made today at the 20th Int...held in Palm Springs, California, on a,non-nucleos...iscovered by Genelabs. , The oral presentation was...of Medicinal Chemistry at Genelabs, entitled,"GL59...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:11/27/2009)...all/--TheGymboreeCorporation(Nasdaq: GYMB )announc...MX23rdInvestorProgram,whichwillbeheldattheMayFairH...11:45a.m.GMT. ,, TolistentoalivebroadcastofTheG...easelogontowww.gymboree.com,clickon"OurCompany"att...ndthen"ConferenceCalls&Webcasts."Thewebcastwil...
(Date:11/27/2009)...e-FirstCall/--ShamirOpticalIndustryLtd.(Nasdaq: SH...ctsandtechnologytotheophthalmiclensmarket,announce...istributioninanaggregateamountofUS$10million(appro...presentativerateofexchange),orapproximatelyUS$0.60...esentativerateofexchange)perordinarysharebasedonth...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...gual coloring books designed for children ages 2 t...o educate - inform parents and children alike on a...rs to ABC,S and a host of other topics. , ...27, 2009 -- Today’s children have enough gad...ur of the day, but one of the oldest and simplest ...
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...swire/ -- WuXi PharmaTech (NYSE:,WX), a leading ph...earch,and development outsourcing company with ope...o announce that the distinguished Stanford Univers...: http://www.newscom.com/cgi-bin/prnh/20040705/CN...
... May 20 Accelerate Brain Cancer,Cure ( http://www...on its,website from leading brain cancer specialis...rain cancer study, as well as valuable guidance fo...ain cancer research and treatment,including:, Dr....
...linic researchers found that the frequency with wh...ssociated pneumonia (VAP) is approximately the sam...yo Clinic compared to the average VAP-risk rate fo...rong across the U.S. in intensive care units, whic...
...scious after swallowing Aqua Dots beads led to a v...t the time, it was widely reported that the potent...used in place of the benign but more expensive 1,5...eports, finding that Aqua Dots contained no 1,5-PD...
...wire/.- Speaker Nancy Pelosi,issued the following ...ennedy,s health:, "The news of Senator Kennedy,s ... Kennedy is a champion for health care for all Ame...e., "Our thoughts and prayers are with him, with ...
... draws specialists from across the ...al Werks, a leading provider of,ceramic components...ices,announced today that the Company will provide...,of disorders of the spine will convene at the Pal...
Other Medicine News:Health News:Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars 2Health News:Brain Cancer Science and Treatment Information 2Health News:Intensive care units' prevention of pneumonia in critically-ill patients generally strong 2Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland 2
Access Vitamin B12
...ked immunosorbent assay (ELISA) for the semi-quant... in human serum. The presence of ANA can be used i...oratory tests to aid in the diagnosis of rheumatic...gren's syndrome, scleroderma, and mixed connective...
...s that are compatible with multichannel pipettors,...ber of pipetting steps required to prepare and pla... Immuno Concepts for more information about this p... noted with an * after the catalog number and are ...
... to screen out patients negative for antinuclear a...mic rheumatic diseases such as Systemic lupus eryt...tive tissue disease, progressive systemic sclerosi... Raynaud's phenomenon. They can also be used in co...
Medicine Products: